Table 1.
Baseline characteristics
| Variable | Metoclopramide + diphenhydramine | Metoclopramide + placebo |
|---|---|---|
| Female, n/N(%) | 88/104 (85%) | 92/104 (89%) |
| Age in years, mean (SD) | 34 (11) | 36 (10) |
| Used medication for headache prior to ED visit, n/N(%) | 66/104 (64%) | 67/103 (65%) |
| Visual Aura1, n/N(%) | 29/104 (28%) | 39/104 (38%) |
| Sensory Aura2, n/N(%) | 5/104 (5%) | 15/104 (14%) |
| Duration of headache in hours, median (IQR) | 72 (24, 96) | 48 (16, 72) |
| Baseline pain on 0–10 scale, median (IQR) | 9 (8, 10) | 9 (8, 10) |
| Number of functionally impairing headaches over previous 90 days, median (IQR) | 3 (1, 5) | 3 (2, 5) |
| Allergic symptoms3, n/N (%) | 15/104 (14%) | 14/104 (14%) |
1
Affirmative response to the following question: “Some people have changes in their vision with their headache. BEFORE YOUR HEADACHE BEGAN, did you see things like spots, stars, lights, zig-zag lines or heat waves?”
2
Affirmative response to the following question: “Some people have changes in their skin sensation with their headache. BEFORE YOUR HEADACHE BEGAN, did you have numbness or tingling in your face or arms?”
3
Score ≥6 on Congestion Quantifier 5 Instrument (Appendix)